Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, et al. Global Cancer Observatory: Cancer Today (version 1.1). Lyon, France: International Agency for Research on Cancer; 2024. Available from: https://gco.iarc.who.int/today
Schiffman M, Doorbar J, Wentzensen N, De Sanjosé S, Fakhry C, Monk BJ, et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Prim 2016;2:16086.
DOI: 10.1038/nrdp.2016.86
Muñoz N, Bosch FX, De Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer. N Engl J Med 2003;348:518-27.
DOI: 10.1056/NEJMoa021641
World Health Organization (WHO). WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition: use of mRNA tests for human papillomavirus (HPV). Geneva: World Health Organization (editor); 2021. Available from: https://www.who.int/publications/i/item/9789240040434
Campos NG, Demarco M, Bruni L, Desai KT, Gage JC, Adebamowo SN, et al. A proposed new generation of evidence-based microsimulation models to inform global control of cervical cancer. Prev Med (Baltim) 2021;144.
DOI: 10.1016/j.ypmed.2021.106438
IARC Handbooks of Cancer Prevention. Cervical cancer screening 2022;18:1-456.
Muñoz N, Castellsagué X, Berrington de González A, Gissmann L. Capítulo 1: El VPH en la etiología del cáncer humano. Vaccine 2006;3:S3/11-S3/10.
DOI: 10.1016/j.vaccine.2006.05.115
Wei F, Georges D, Man I, Baussano I, Clifford G. Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature. Lancet 2024;404(10451):435-44.
DOI: 10.1016/S0140-6736(24)01097-3
Torné A, Andía D, Bruni L, Centeno C, Coronado P, Cruz Quílez J, et al. AEPCC-Guía: Prevención secundaria del cancer de cuello del útero, 2022. Conducta clínica ante resultados anormales de las pruebas de cribado. En: Del Pino M, Tornè A (editors). AEPCC; 2022. p. 133. Available from: https://www.aepcc.org/wp-content/uploads/2022/11/Guia-Prevencion-cancer-cervix-2022.pdf
Malagón T, Franco EL, Tejada R, Vaccarella S. Epidemiology of HPV-associated cancers past, present and future: towards prevention and elimination. Nat Rev Clin Oncol 2024;21(7):522-38.
DOI: 10.1038/s41571-024-00904-z
Kelly H, Weiss HA, Benavente Y, De Sanjose S, Mayaud P, Qiao Y lin, et al. Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis. Lancet HIV 2018;5(1):e45-58.
DOI: 10.1016/S2352-3018(17)30149-2
Malvolti S, Soble A, Bloem P, LaMontagne DS, Aggarwal R, Pitisuttithum P, et al. The Global Demand and Supply Balance of the Human Papillomavirus Vaccine: Implications for the Global Strategy for the Elimination of Cervical Cancer. Vaccines 2024;12(1):4.
DOI: 10.3390/vaccines12010004
Whitworth HS, Mounier-Jack S, Choi EM, Gallagher KE, Howard N, Kelly H, et al. Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to multidose vaccination regimens or no vaccination: An updated systematic review of evidence from clinical trials. Vaccine X 2024;19:100486.
DOI: 10.1016/j.jvacx.2024.100486
World Health Organization (WHO). Human papillomavirus vaccines: WHO position paper, December 2022. Weekly Epidemiological Record 2022;97(50):645-72. Available from: https://www.who.int/publications/i/item/who-wer9750-645-672
Tsang SH, Sampson JN, Schussler J, Porras C, Wagner S, Boland J, et al. Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: The CVT Trial. J Natl Cancer Inst 2020;112(10):1030-7.
DOI: 10.1093/jnci/djaa010
Bruni L, Díaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: A pooled analysis. Lancet Glob Heal 2016;4(7):e453-63.
DOI: 10.1016/S2214-109X(16)30099-7
Brotons M, Monfil L, Roura E, Duarte-Salles T, Casabona J, Urbiztondo L, et al. Impact of a single-age cohort human papillomavirus vaccination strategy in Catalonia, Spain: Population-based analysis of anogenital warts in men and women. Prev Med (Baltim) 2020;138:106166.
DOI: 10.1016/j.ypmed.2020.106166
Lei J, Ploner A, Elfström KM, Wang J, Roth A, Fang F, et al. HPV Vaccination and the Risk of Invasive Cervical Cancer. N Engl J Med 2020;383(14):1340-8.
DOI: 10.1056/NEJMoa1917338
Falcaro M, Castañón A, Ndlela B, Checchi M, Soldán K, López-Bernal J, et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet (London, England) 2021;398(10316):2084-92.
DOI: 10.1016/S0140-6736(21)02178-4
Palmer MR, Saito E, Katanoda K, Sakamoto H, Hocking JS, Brotherton JML, et al. The impact of alternate HPV vaccination and cervical screening strategies in Japan: a cost-effectiveness analysis. Lancet Reg Heal-West Pacific 2024;44:101018.
DOI: 10.1016/j.lanwpc.2024.101018
Kjaer SK, Dehlendorff C, Belmonte F, Baandrup L. Real-World Effectiveness of Human Papillomavirus Vaccination Against Cervical Cancer. J Natl Cancer Inst 2021;113(10):1329-35.
DOI: 10.1093/jnci/djab080
Moscicki A-B, Schiffman M, Burchell A, Albero G, Giuliano AR, Goodman MT, et al. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 2012;30(Suppl.5):F24-33.
DOI: 10.1016/j.vaccine.2012.05.089
World Health Organization (WHO). WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition. Geneva: World Health Organization (WHO); 2021. Available from: https://www.who.int/publications/i/item/9789240030824
Bruni L, Serrano B, Roura E, Alemany L, Cowan M, Herrero R, et al. Articles Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide : a review and synthetic analysis. Lancet Glob Heal 2022;10(8):e1115-27.
DOI: 10.1016/S2214-109X(22)00241-8
Quinn M, Babb P, Jones J, Allen E. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ 1999;318(7188):904-8.
DOI: 10.1136/bmj.318.7188.904
Goldie SJ, Kim JJ, Myers E. Chapter 19: Cost-effectiveness of cervical cancer screening. Vaccine 2006;24(Suppl.3):S3/164-70 [cited 2013 Oct 6].
DOI: 10.1016/j.vaccine.2006.05.114
Sankaranarayanan R, Nene B, Dinshaw K, Mahe C, Jayant K, Shastri S, et al. A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India. Int J Cancer 2005;116(4):617-23.
DOI: 10.1002/ijc.21050
Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJF, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: Follow-up of four European randomised controlled trials. Lancet 2014;383(13):524-32.
DOI: 10.1016/S0140-6736(13)62218-7
Rayner M, Welp A, Stoler MH, Cantrell LA. Cervical Cancer Screening Recommendations: Now and for the Future. Healthcare 2023;11(16).
DOI: 10.3390/healthcare11162273
Council of the European Union. Council Recommendation on strengthening prevention through early detection: A new EU approach on cancer screening replacing Council Recommendation 2003/878/EC; 2022. Available from: https://data.consilium.europa.eu/doc/document/ST-14770-2022-INIT/en/pdf
Rivm. Cervical Cancer Population Screening in the Netherlands. Factsheet 2021. 2022;(July 2020).
NKCx Steering and Expert committee. Swedish National Cervical Screening Registry_Analysis. Available from: https://nkcx.se/index_e.htm
Bruni L, Serrano B, Roura E, Alemany L, Cowan M, Herrero R, et al. Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis. Lancet Glob Heal 2022;10(8):e1115-27.
DOI: 10.1016/S2214-109X(22)00241-8
Ministerio de Sanidad Consumo y Bienestar Social. Orden SCB/480/2019, de 26 de abril, por la que se modifican los anexos I, III y VI del Real Decreto 1030/2006, de 15 de septiembre, que establece la cartera de servicios comunes del Sistema Nacional de Salud y el procedimiento para su actualización. BOE Núm. 1, Sec. 1, página 43018; 2019. Disponible en: https://www.boe.es/eli/es/o/2019/04/26/scb480
Grupo de trabajo de Cribado de Cáncer de Cérvix de la Ponencia de Cribado Poblacional de la Comisión de Salud, Pública. Documento de consenso sobre la modificación del Programa de Cribado de Cáncer de Cérvix. Adaptación de la edad de inicio del cribado primario con prueba VPH y de la del cribado en cohortes vacunadas; 2023. Available from: https://www.sanidad.gob.es/areas/promocionPrevencion/cribado/cribadoCancer/cancerCervix/docs/DocumentoconsensomodificacionCervix.pdf
Ministerio de Sanidad Consumo y Bienestar Social. Encuesta Nacional de Salud de España. Disponible en: https://www.mscbs.gob.es/estadEstudios/estadisticas/encuestaNacional/home.htm
Ibáñez R, Autonell J, Sardà M, Crespo N, Pique P, Pascual A, et al. Protecting the underscreened women in developed countries: the value of HPV test. BMC Cancer 2014;14(1):574.
DOI: 10.1186/1471-2407-14-574
Castillo M, Astudillo A, Clavero O, Velasco J, Ibáñez R, Desanjosé S. Poor cervical cancer screening attendance and false negatives. A call for organized screening. PLoS One 2016;11(8):1-9.
Organización Mundial de la Salud (OMS). Estrategia mundial para acelerar la eliminación del cáncer del cuello uterino como problema de salud pública [Global strategy to accelerate the elimination of cervical cancer as a public health problem]. Ginebra: Organización Mundial de la Salud; 2022.
Número de descargas:
1555
Número de visitas:
100
Citas:
0
